Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POEM pilot dose-escalation trial with EMP16
2024-520122-11-00Phase 2Completed
- Sponsor
- Empros Pharma
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in obesity comparing EMP16 + Vi-Siblin S with Conventional orlistat + placebo fibre (2 arms). Primary endpoint: Total GITE1 score difference. Started Apr 2025; status: completed.
02
Drugs
EMP16
03
Conditions
obesity
Beyond the preview
Go deeper on 2024-520122-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520122-11-00.